Database crunches pharma's HCP payments

Share this article:
In the run-up to 2013, when federal law will require pharma and device firms to file annual public reports of gifts and payments to doctors and teaching hospitals in excess of $10, several firms are disclosing voluntarily, or as part of corporate integrity agreements. But it's hard to glean a big picture on these financial relationships from raw data.

George Dunston left his job as an in-house counsel at Merck in 2008 to form Obsidian HDS, which aims to gather and present this data in a more usable format. This month the two-year-old firm is ending its trial phase to offer paid subscriptions (consumers will still be able to view and search certain portions for free). So far, registrants include about 40 medical schools, 30 hospitals, as well as individual physicians, pharma companies and marketing and med ed vendors.

“We're closing in on about 100 different industry-related professionals who have registered with us, including from eight of the top 10 largest US pharma companies,” Dunston told MM&M.

Besides providing more data for systems, like Obsidian, that allow organizations to manage payment data, the Physician Sunshine Payment Act “will spark more interest,” said Dunston.

So far one trend jumps out: “A fairly large number of physicians are receiving these types of payments,” said Dunston. “We have over 27,000 physicians in our database so far.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?